Image Place holder

Melissa McGettigan, MD


Specialty: Radiology
Program: Diagnostic Imaging and Interventional Radiology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Anal Cancer, Appendiceal (Appendix) Cancer, Bladder Cancer, Cholangiocarcinoma (Bile Duct Cancer), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor, GIST (Gastrointestinal Stromal Tumor), Kidney (Renal Cell) Cancer, Liver Cancer, Neuroendocrine Tumor, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer, Testicular Cancer, Penile Cancer

Dr. McGettigan received her Doctor of Medicine degree from the University of South Florida College of Medicine in Tampa, FL. She completed a Diagnostic Radiology Residency at Medical College of Georgia where she also served as Assistant Chief Resident. Dr. McGettigan completed an Abdominal Imaging Fellowship at Mallinckrodt Institute of Radiology in St. Louis, Missouri. Dr. McGettigan’s most recent affiliation was with the Radiology Associates of St. Petersburg. Dr. McGettigan joined Moffitt Cancer Center in 2016. Her clinical interests are in gastrointestinal and genitourinary radiology and non- vascular image-guided procedures. Her research interests include applications of MRI for prostate cancer and ultrasound for radiation dose reduction in diagnosis and therapeutic intervention of gastrointestinal and genitourinary malignancies. 

Education & Training

Fellowship:

  • Mallinckrodt Institute of Radiology - Abdominal Imaging

Residency:

  • Medical College of Georgia - Radiology

Medical School:

  • University of South Florida - MD
Participating Trials

CLINICAL TRIAL 18675
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Condition:
Intervention: 5-fluorouracil; CPT-11 (irinotecan); Camptosar (irinotecan); Oxaliplatin; eloxatin (Oxaliplatin); irinotecan; leucovorin
Open

CLINICAL TRIAL 18684
A Phase II Investigator Sponsored Study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Liu Y, Wang H, Li Q, McGettigan MJ, Balagurunathan Y, Garcia AL, Thompson ZJ, Heine JJ, Ye Z, Gillies RJ, Schabath MB. Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology. 2018 Jan;286(1):298-306. Pubmedid: 28837413. Pmcid: PMC5738292.
  • McGettigan MJ, Gatenby RA. Radiologic Pearls for Internists: A Case-Based Review. Am J Med. 2018 Jan;131(1):9-16. Pubmedid: 28889930.
  • Woodall MN, McGettigan M, Figueroa R, Gossage JR, Alleyne CH. Cerebral vascular malformations in hereditary hemorrhagic telangiectasia. J Neurosurg. 2014 Jan;120(1):87-92. Pubmedid: 24236651.
  • Carvalho KM, McGettigan MJ, Martin DF. GC/MS analysis of volatile organic selenium species produced during phytoremediation. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2001 Sep;36(7):1403-1409. Pubmedid: 11545362.
  • McGettigan MJ, Menias CO, Gao ZJ, Mellnick VM, Hara AK. Imaging of Drug-induced Complications in the Gastrointestinal System. Radiographics. 36(1):71-87. Pubmedid: 26761532.